Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

Key Highlights



Nominated EB-373 as lead development candidate for the treatment of anxiety disorders



EB-373 is a next generation proprietary psilocin prodrug selected from Enveric’s... | April 3, 2023

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Australia ,Australian ,Kevin Coveney ,Joseph Tucker ,Enveric Biosciences ,Enveric Biosciences Inc ,Akos Biosciences Inc ,Acanna Therapeutics Inc ,Nasdaq ,Therapeutic Goods Administration ,Enveric Therapeutics ,Avance Clinical ,Pipeline Targeting Unmet Needs ,Leading Developer ,Novel Small Molecule Therapeutics ,Akos Biosciences ,Acanna Therapeutics ,Chief Financial Officer ,Lynn Gallant ,Vice President ,Clinical Operations ,Intellectual Property ,New Chemical Entities ,Nc Stock Exchange ,News ,Information ,Press Release ,Key ,Us ,Head ,Development ,Candidate ,Or ,The ,Treatment ,F ,Anxiety ,Text ,Generation ,Roprietary ,Psilocin ,Prodrug ,Elected ,Rom Envb Us29405e2081 ,